Shares of Precigen have increased after the company’s Phase 1b/2a study of its AG019 ActoBiotics, designed to address the underlying cause of Type 1 diabetes. The treatment was studied in Phase 1b as a monotherapy for adults aged 18–42 and adolescents aged 12–17. In Phase 2a, it was used as a combination therapy with teplizumab.
“We are encouraged by the Phase 1b/2a primary analysis results and the implications for the potential of AG019 as an easy-to-take oral monotherapy or combination therapy with teplizumab,” Pieter Rottiers, chief executive of Precigen’s ActoBio division, said in a statement. He added that the results, “suggest the ability of AG019 to modulate a patient’s immune system in a precise, antigen-specific manner to address the underlying cause of Type 1 diabetes.”
